AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7887719 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm cardioplegia (37 degrees C)
Number of subjects: 42
Study 7887719 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold cardioplegia (9 degrees C)
Number of subjects: 42
Study 2222242 — intervention group
Group type: EXPERIMENTAL
Intervention: Best medical management
Number of subjects: 21
Study 2222242 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical evacuation
Number of subjects: 21
Study 2222242 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial pressure monitoring
Number of subjects: 21
Study 2222242 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall outcomes
Number of subjects: 21
Study 360819 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential amino acids (15.7 g daily for 3 months)
Number of subjects: 13
Study 360819 — intervention group
Group type: COMPARATOR
Intervention: Liberal diet (1 g protein/kg body weight)
Number of subjects: 13
Study 31243158 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive SR teddy bear
Number of subjects: 54
Study 31243158 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based avatar version of the bear
Number of subjects: 54
Study 31243158 — intervention group
Group type: COMPARATOR
Intervention: Plush teddy bear with human presence
Number of subjects: 54
Study 28260864 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 5 mg/day or 10 mg/day plus HBO therapy
Number of subjects: 120
Study 28260864 — intervention group
Group type: COMPARATOR
Intervention: HBO therapy as monotherapy
Number of subjects: 120
Study 26198966 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 0.5 mg/kg lidocaine and 0.5 mg/kg ketamine, followed by continuous infusion of lidocaine at 0.5 mg·kg(‐1)·h(‐1) till the end of the operation
Number of subjects: 60
Study 26198966 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion only
Number of subjects: 60
Study 23260855 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (ethinyl E2 and desogestrel) for 9 weeks
Number of subjects: 42
Study 23260855 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal patches (ethinyl E2 and norelgestromin) for 9 weeks
Number of subjects: 42
Study 23260855 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal rings (ethinyl E2 and etonogestrel) for 9 weeks
Number of subjects: 42
Study 21278401 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (MTZ) single-dose 2 g
Number of subjects: 244
Study 19891046 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose cyclosporine
Number of subjects: 1645
Study 19891046 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab induction plus low-dose cyclosporine
Number of subjects: 1645
Study 19891046 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose tacrolimus
Number of subjects: 1645
Study 19891046 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose sirolimus
Number of subjects: 1645
Study 17403857 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Botulism Immune Globulin
Number of subjects: 681
Study 15482753 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam (10 mg orally) before embryo transfer in fresh cycles
Number of subjects: 188
Study 15482753 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam (10 mg orally) before embryo transfer in frozen-thawed cycles
Number of subjects: 188
Study 15482753 — intervention group
Group type: COMPARATOR
Intervention: Placebo before embryo transfer in fresh cycles
Number of subjects: 188
Study 15482753 — intervention group
Group type: COMPARATOR
Intervention: Placebo before embryo transfer in frozen-thawed cycles
Number of subjects: 188
Study 11685412 — intervention group
Group type: EXPERIMENTAL
Intervention: Small apertures with varying size and shape
Number of subjects: 0
Study 11685412 — intervention group
Group type: EXPERIMENTAL
Intervention: Location of stimulus in the visual field
Number of subjects: 0
Study 11685412 — intervention group
Group type: COMPARATOR
Intervention: Overall duration of the stimulus
Number of subjects: 0
Study 9778615 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (OND) 8 mg every 6 hours for the first 24 hours (total of 4 doses)
Number of subjects: 110
Study 9778615 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (OND) 32 mg as a loading dose before cisplatin, total dose for the first 24 hours
Number of subjects: 110
Study 9778615 — intervention group
Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 110
Study 8880045 — intervention group
Group type: EXPERIMENTAL
Intervention: Draflazine 3.5 mg
Number of subjects: 21
Study 8880045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 2397974 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% PVP‐iodine solution and 50% salicylic acid plaster therapy
Number of subjects: 20
Study 2397974 — intervention group
Group type: COMPARATOR
Intervention: Control group (lacked either one of the applications)
Number of subjects: 20
Study 7197979 — intervention group
Group type: EXPERIMENTAL
Intervention: amezinium (10 mg i.v.)
Number of subjects: 29
Study 7197979 — intervention group
Group type: EXPERIMENTAL
Intervention: norfenefrine (10 mg i.m.)
Number of subjects: 29
Study 7197979 — intervention group
Group type: EXPERIMENTAL
Intervention: dihydroergotamine (1 mg i.m.)
Number of subjects: 29
Study 7197979 — intervention group
Group type: COMPARATOR
Intervention: control test
Number of subjects: 29
Study 31045821 — intervention group
Group type: COMPARATOR
Intervention: Desflurane anesthesia
Number of subjects: 50
Study 31045821 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol total intravenous anesthesia (TIVA)
Number of subjects: 50
Study 28506548 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic medication (AAD)
Number of subjects: 260
Study 28506548 — intervention group
Group type: COMPARATOR
Intervention: Catheter ablation (CA)
Number of subjects: 260
Study 25839374 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral nutrition
Number of subjects: 102
Study 25839374 — intervention group
Group type: COMPARATOR
Intervention: Nutrition education
Number of subjects: 102
Study 22431446 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP (6 cmH2O pressure support for 6 hours)
Number of subjects: 19
Study 22431446 — intervention group
Group type: COMPARATOR
Intervention: Control (air/oxygen mixture from heated humidifier for 6 hours)
Number of subjects: 19
Study 21091546 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% probiotic
Number of subjects: 375
Study 21091546 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% probiotic
Number of subjects: 375
Study 21091546 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% probiotic
Number of subjects: 375
Study 21091546 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% probiotic
Number of subjects: 375
Study 21091546 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% to 0.5% probiotic
Number of subjects: 375
Study 21091546 — intervention group
Group type: COMPARATOR
Intervention: Control (0% probiotic)
Number of subjects: 375
Study 19021788 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapies published as case reports (CRs)
Number of subjects: 31
Study 19021788 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 31
Study 17556695 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-containing functional food (300 mg DHA/92-kcal bar; average consumption: 5 bars/wk)
Number of subjects: 29
Study 17556695 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cereal-based bars)
Number of subjects: 29
Study 15121876 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg
Number of subjects: 14
Study 15121876 — intervention group
Group type: COMPARATOR
Intervention: Control (no mifepristone)
Number of subjects: 14
Study 11448466 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg/day NES
Number of subjects: 87
Study 11448466 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 microg/day NES
Number of subjects: 87
Study 11448466 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg/day NES
Number of subjects: 87
Study 8822534 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 +/- 2.5 mg/day (Olz-M)
Number of subjects: 335
Study 8822534 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 15 +/- 2.5 mg/day (Olz-H)
Number of subjects: 335
Study 8822534 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 15 +/- 5 mg/day (Hal)
Number of subjects: 335
Study 8822534 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 5 +/- 2.5 mg/day (Olz-L)
Number of subjects: 335
Study 8822534 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 335
Study 1424412 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg
Number of subjects: 8
Study 1424412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3918734 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 10
Study 3918734 — intervention group
Group type: COMPARATOR
Intervention: Control (no naloxone)
Number of subjects: 10
Study 31206808 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC-ER 0.15 mg/kg/day based on adjusted body weight (aBW)
Number of subjects: 20
Study 31206808 — intervention group
Group type: COMPARATOR
Intervention: TAC-ER 0.15 mg/kg/day based on ideal body weight (IBW)
Number of subjects: 20
Study 29501363 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (80 mg/m2 intravenously weekly for 12 doses) plus carboplatin (area under the curve 6 mg/mL per min, intravenously every 3 weeks, for four cycles) plus veliparib (50 mg orally, twice a day)
Number of subjects: 634
Study 29501363 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus carboplatin
Number of subjects: 634
Study 29501363 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel alone
Number of subjects: 634
Study 29501363 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (with or without veliparib)
Number of subjects: 634
Study 29501363 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib
Number of subjects: 634
Study 29501363 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 634
Study 27922288 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate rehabilitation (physical therapy from day 1 to day 84)
Number of subjects: 26
Study 27922288 — intervention group
Group type: COMPARATOR
Intervention: Traditional rehabilitation (physical therapy from day 29 to day 84)
Number of subjects: 26
Study 24978952 — intervention group
Group type: EXPERIMENTAL
Intervention: RA+ (risk-assessment questionnaire plus nasal flow monitor)
Number of subjects: 325
Study 24978952 — intervention group
Group type: COMPARATOR
Intervention: RAO (risk-assessment-only questionnaire)
Number of subjects: 325
Study 24978952 — intervention group
Group type: COMPARATOR
Intervention: RAO
Number of subjects: 325
Study 24978952 — intervention group
Group type: EXPERIMENTAL
Intervention: RA+
Number of subjects: 325
Study 22777673 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial ATP infusions
Number of subjects: 16
Study 22777673 — intervention group
Group type: EXPERIMENTAL
Intervention: KCl infusion
Number of subjects: 16
Study 22777673 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined infusion of ouabain and barium chloride (BaCl2)
Number of subjects: 16
Study 22777673 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ouabain plus BaCl2 infusion
Number of subjects: 16
Study 22777673 — intervention group
Group type: EXPERIMENTAL
Intervention: BaCl2 alone
Number of subjects: 16
Study 20362915 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional glass ionomer cement (GIC)
Number of subjects: 60
Study 20362915 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin modified glass ionomer cement (RMGIC)
Number of subjects: 60
Study 20362915 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyacid-modified composite
Number of subjects: 60
Study 17568245 — intervention group
Group type: EXPERIMENTAL
Intervention: Red yeast rice (600 mg, twice daily for 8 weeks)
Number of subjects: 79
Study 17568245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 16128784 — intervention group
Group type: EXPERIMENTAL
Intervention: Covered expandable metallic stents
Number of subjects: 22
Study 12137831 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser prostatectomy
Number of subjects: 100
Study 12137831 — intervention group
Group type: COMPARATOR
Intervention: TURP
Number of subjects: 100
Study 9973020 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced diuresis with intravenous crystalloid, furosemide, mannitol (if pulmonary capillary wedge pressure <20 mm Hg), and low-dose dopamine (n = 43)
Number of subjects: 98
Study 9973020 — intervention group
Group type: COMPARATOR
Intervention: Intravenous crystalloid and matching placebos (n = 55)
Number of subjects: 98
Study 9973020 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined analysis of all participants
Number of subjects: 98
Study 7568389 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced examiners (1 male, 1 female)
Number of subjects: 22
Study 7568389 — intervention group
Group type: EXPERIMENTAL
Intervention: Inexperienced examiners (1 male, 1 female)
Number of subjects: 22
Study 7568389 — intervention group
Group type: EXPERIMENTAL
Intervention: 67‐N, 89‐N, maximum manual, and active anterior drawer tests
Number of subjects: 22
Study 1960071 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-ETS with 100% tidal volume (VT)
Number of subjects: 30
Study 1960071 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-ETS with 135% tidal volume (VT)
Number of subjects: 30
Study 1960071 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-ETS with 100% tidal volume (VT)
Number of subjects: 30
Study 1960071 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-ETS with 135% tidal volume (VT)
Number of subjects: 30
Study 1960071 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 30
Study 7072998 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane, 0.3 to 0.8 per cent, and oxygen (Group 2)
Number of subjects: 61
Study 7072998 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide, 30 to 50 per cent, and oxygen (Group 3)
Number of subjects: 61
Study 7072998 — intervention group
Group type: COMPARATOR
Intervention: No inhalation agent (Group 1)
Number of subjects: 61
Study 31225821 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta burst repetitive transcranial magnetic stimulation (active treatment)
Number of subjects: 40
Study 31225821 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (sham treatment)
Number of subjects: 40
Study 28863874 — intervention group
Group type: EXPERIMENTAL
Intervention: PTV/EPA (PTV 4mg/day and EPA 1800mg/day)
Number of subjects: 193
Study 28863874 — intervention group
Group type: COMPARATOR
Intervention: PTV (PTV 4mg/day)
Number of subjects: 193
Study 26786266 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry packing
Number of subjects: 201
Study 26786266 — intervention group
Group type: EXPERIMENTAL
Intervention: Packing soaked with water
Number of subjects: 201
Study 26786266 — intervention group
Group type: EXPERIMENTAL
Intervention: Packing soaked with chlorhexidine gluconate and benzydamine hydrochloride
Number of subjects: 201
Study 26786266 — intervention group
Group type: COMPARATOR
Intervention: No packing
Number of subjects: 201
Study 25168853 — intervention group
Group type: EXPERIMENTAL
Intervention: Group tai chi program (N = 63)
Number of subjects: 125
Study 25168853 — intervention group
Group type: COMPARATOR
Intervention: Time/attention-matched education control (N = 31)
Number of subjects: 125
Study 25168853 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind-body breathing program (N = 31)
Number of subjects: 125
Study 25168853 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup of patients in tai chi (N = 50)
Number of subjects: 125
Study 25168853 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi program (N = 63)
Number of subjects: 125
Study 22520304 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation tool for assessing surgical technique of capsulorhexis
Number of subjects: 6
Study 22520304 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Likert-scale questions grading flow of operation, set up for regrasp, commencement of flap and formation, and circular completion of the CCC
Number of subjects: 6
Study 19251584 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (440 microg twice daily)
Number of subjects: 12
Study 19251584 — intervention group
Group type: COMPARATOR
Intervention: Oral montelukast (10 mg/day)
Number of subjects: 12
Study 19251584 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 12
Study 17237724 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate supplementation in combination with other treatments for IBD
Number of subjects: 41
Study 17237724 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 41
Study 17237724 — intervention group
Group type: EXPERIMENTAL
Intervention: Crohn's disease (CD)
Number of subjects: 41
Study 17237724 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulcerative colitis (UC)
Number of subjects: 41
Study 17237724 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood lymphocytes in UC patients
Number of subjects: 41
Study 15764422 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg fluoxetine
Number of subjects: 150
Study 15764422 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg fluoxetine
Number of subjects: 150
Study 15764422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 15764422 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg and 40 mg)
Number of subjects: 150
Study 15764422 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 150
Study 11270907 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (2.5 mg)
Number of subjects: 2
Study 11270907 — intervention group
Group type: COMPARATOR
Intervention: Middle-aged women
Number of subjects: 2
Study 11270907 — intervention group
Group type: COMPARATOR
Intervention: Middle-aged group
Number of subjects: 2
Study 9721958 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg once daily for 3 days
Number of subjects: 169
Study 9721958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study 9721958 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 169
Study 7988776 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-hour local hyperglycaemia (5% glucose infusion)
Number of subjects: 12
Study 7988776 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl infusion)
Number of subjects: 12
Study 2971693 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical isotretinoin (0.05%)
Number of subjects: 0
Study 2971693 — intervention group
Group type: COMPARATOR
Intervention: Topical tretinoin (0.05%)
Number of subjects: 0
Study 31125055 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg vaccine (month regimen)
Number of subjects: 855
Study 31125055 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg vaccine (month regimen)
Number of subjects: 855
Study 31125055 — intervention group
Group type: EXPERIMENTAL
Intervention: month regimen
Number of subjects: 855
Study 31125055 — intervention group
Group type: EXPERIMENTAL
Intervention: day regimen
Number of subjects: 855
Study 31125055 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 855
Study 31086354 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced nutrient supply
Number of subjects: 50
Study 31086354 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 28024163 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation group (PEG) intervention program, delivered weekly in a group format over 3 weeks
Number of subjects: 72
Study 28024163 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation group (PEG) intervention program
Number of subjects: 72
Study 28024163 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 72
Study 25926006 — intervention group
Group type: EXPERIMENTAL
Intervention: Large portion size (two-thirds of a cucumber)
Number of subjects: 255
Study 25926006 — intervention group
Group type: COMPARATOR
Intervention: Small portion size (one-third of a cucumber)
Number of subjects: 255
Study 25926006 — intervention group
Group type: EXPERIMENTAL
Intervention: Large unit size (one piece of cucumber)
Number of subjects: 255
Study 25926006 — intervention group
Group type: COMPARATOR
Intervention: Small unit size (pre-sliced cucumber)
Number of subjects: 255
Study 22676906 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface neuromuscular electrical stimulation for 30 minutes, twice a day for 6 weeks in addition to standardized upper limb therapy
Number of subjects: 90
Study 22676906 — intervention group
Group type: COMPARATOR
Intervention: Standardized upper limb therapy alone
Number of subjects: 90
Study 20443105 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte esterase reagent (LER) strip test with purple-color cut-off (>500 PMNL/microL)
Number of subjects: 175
Study 20443105 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte esterase reagent (LER) strip test with light-blue color cut-off (>125 PMNL/microL)
Number of subjects: 175
Study 18029341 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasaleze cellulose with powdered garlic extract (PGE)
Number of subjects: 52
Study 18029341 — intervention group
Group type: COMPARATOR
Intervention: Control group (Nasaleze cellulose alone)
Number of subjects: 52
Study 16202939 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance supply of emergency contraception (AEC)
Number of subjects: 160
Study 16202939 — intervention group
Group type: COMPARATOR
Intervention: Control group (information only)
Number of subjects: 160
Study 12369021 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic personal provision of clinically based information at 15-minute intervals during ED visit
Number of subjects: 619
Study 12369021 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic personal provision of clinically based information
Number of subjects: 619
Study 12369021 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (no additional information provided)
Number of subjects: 619
Study 10197566 — intervention group
Group type: EXPERIMENTAL
Intervention: 4500 RE (15000 IU) vitamin A/d for ≤ 12 years (group A)
Number of subjects: 146